Settlement Reached in Misconduct Case

A cancer researcher found guilty of misconduct has reached a settlement with the ORI that allows him to apply for federal research funding.

Written byDan Cossins
| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

WIKIMEDIA, GALLO & SPERO LLPThe Office of Research Integrity (ORI) has reached a settlement agreement with cancer biologist and biochemist Phillippe Bois, who was found guilty of research misconduct in 2011 and barred from applying for federal grants for 3 years. Bois filed a lawsuit to the District Court to overturn the penalty, and the subsequent settlement means he is eligible to apply for federal research funding—though he will no longer seek to appeal the ORI’s findings, according to an announcement published yesterday (April 18) in the Federal Register.

“I have been fighting to clear my name for almost 7 years, and I am glad to be able to put this matter behind and to move on with my career in science,” said Bois in a statement released by his defense attorneys. “ORI’s decision to cease seeking a debarment is a clear signal to me that its findings would not have been sustained by a judge and that its proposed punishment, a three-year debarment, was excessive and unreasonable.”

In May 2011 the ORI found that Bois had committed two counts of research misconduct while working at St. Jude Children’s Research Hospital in Memphis, Tennessee: he had falsified an image to conceal unwanted results for a paper in the Journal of Cell Biology, which was ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies